Amgen Inc 's Revenue in the fiscal year 2025 $ 36,751.00 millions
Amgen Inc 's Revenue in the fiscal year 2024 $ 33,424.00 millions
Amgen Inc 's Revenue in the fiscal year 2023 $ 28,190.00 millions
Amgen Inc 's Revenue in the fiscal year 2022 $ 26,323.00 millions
Amgen Inc 's Revenue in the fiscal year 2021 $ 25,979.00 millions
AMGN Revenue second quarter 2026 Y/Y Growth Comment
Amgen Inc achieved in the second quarter 2026, above Company average Revenue improvement of 9.53% year on year, to $ 10,054.00 millions.
Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 38 other companies have achieved higher Revenue growth. While Amgen Inc ' s Revenue increase of 9.53% ranks overall at the positon no. 2390 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Amgen Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
18.73 %
1.85 %
-12.65 %
(Dec 31 2023)
AMGN's II. Quarter Q/Q Revenue Comment
Amgen Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 16.66%, to $ 10,054.00 millions, from $8,618.00 millions in the first quarter. AMGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Amgen Inc 's Revenue growth quarter on quarter, overall rank is 593.
Amgen Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 16.66%, to $ 10,054.00 millions, from $8,618.00 millions in the first quarter. AMGN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Amgen Inc 's Revenue growth quarter on quarter, overall rank is 593.
Amgen Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 38,095.00
$ 37,220.00
$ 36,751.00
$ 35,971.00
$ 34,917.00
Y / Y Revenue Growth (TTM)
9.1 %
9.07 %
9.95 %
10.56 %
12.88 %
Year on Year Revenue Growth Overall
Ranking
# 1256
# 426
# 139
# 752
# 912
Seqeuential Revenue Change (TTM)
2.35 %
1.28 %
2.17 %
3.02 %
2.32 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2390
# 1355
# 547
# 754
# 1566
Cumulative Revenue growth Comment
Amgen Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 9.1% year on year, to $ 38,095 millions if the fiscal year would have ended in Jun 30 2026. Amgen Inc 's trailing twelve months Revenue growth was higher than company's average 6.19% and higher than 9.07% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 2.35 % from $37220 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at6.19%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 2.35 % increase from $37220 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 222 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 426 to 1256.
Amgen Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 9.1% year on year, to $ 38,095 millions if the fiscal year would have ended in Jun 30 2026. Amgen Inc 's trailing twelve months Revenue growth was higher than company's average 6.19% and higher than 9.07% growth in Mar 31 2026. But from twelve months ended Mar 31 2026 rise was beneth at 2.35 % from $37220 millions achieved in the period from Mar 31 2026 to Jun 30 2025. We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at6.19%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 2.35 % increase from $37220 millions in the period from Mar 31 2026 to Jun 30 2025.
In the Healthcare sector 222 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 426 to 1256.
About Amgen Inc Revenue Growth Rates (AMGN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
16.65%